Skip to main content
. 2021 Sep 20;7(10):e765. doi: 10.1097/TXD.0000000000001221

TABLE 2.

Characteristics of 11 deaths in the cohort during extended follow-up

Patient Baseline Immunosuppression Immunosuppression switch Cause of switch (d post-LTx to switch) Cause of death Time to death post-LTx, d Primary graft (if not, cause of retransplantation) Related to surgery or immunosuppression
1 CyA-ME No Intractable seizures 473 Yes Seizures related to CyA-ME use
2 CyA-ME Yes (Tac) 3rd episode of acute rejection (233) CLF and HOCM 576 No (PVT) CLF related to PVT after surgery. HOCM related to Tac use
3 CyA-ME No PTLD 1041 Yes Related to immunosuppression
4 Tac No GI bleed 637 Yes Surgical—Budd-Chiari
5 Tac No PTLD 658 Yes Related to immunosuppression
6 Tac Yes (CyA-ME) Renal dysfunction (162) Unknown 853 Yes Unknown
7 CyA-ME Yes (Tac) Chronic rejection (520) Multiple organ failure 4188 No (cryptogenic cirrhosis) Unknown
8 CyA-ME No GI bleed 2221 Yes Unknown
9 Tac No Respiratory failure and sepsis 2523 Yes CF related
10 CyA-ME Yes (Tac) Steroid-resistant rejection (25) Intraoperative death 2749 No (chronic rejection) Complications during surgery
11 Tac No Hemolytic anemia causing multiorgan failure 3085 Yes Pulmonary hypertension + noncompliant

CF, cystic fibrosis; CLF, chronic liver failure; CyA-ME, cyclosporine A microemulsion; GI, gastrointestinal; HOCM, hypertrophic cardiomyopathy; LTx, liver transplantation; PTLD, posttransplant lymphoproliferative disease; PVT, portal vein thrombosis; Tac, tacrolimus.